Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new phase 4 trial shows that monthly infusions of higher-dose pegloticase paired with methotrexate successfully lowered uric acid levels in over two-thirds of patients with hard-to-treat gout. The combo held uric acid below the target threshold through most of month 6, though gout flares and infusion reactions were common. Researchers say the monthly schedule could ease the treatment burden compared to more frequent dosing.
Tackling tough gout with a monthly combo punch
For patients whose gout just won't quit, a new phase 4 trial offers some encouraging news. Monthly infusions of higher-dose pegloticase — at either 16 mg or 30 mg — combined with oral methotrexate kept serum uric acid levels below the 6 mg/dL target in more than two-thirds of patients through most of month 6. Among those who continued into a 12-month extension, response rates climbed even higher in the 16 mg group.
The trade-off? Side effects were common. Gout flares hit roughly three-quarters of patients in both dose groups, and infusion reactions — including some cases of anaphylaxis — occurred in about 12–16% of participants. Most adverse events were mild to moderate and didn't lead to treatment discontinuation.
By the Numbers:
Why it matters: Uncontrolled gout is notoriously difficult to manage, and current pegloticase regimens require biweekly infusions — a logistical challenge for patients and clinics alike. A monthly dosing schedule could meaningfully reduce that burden, though the authors note that patient adherence and healthcare resource use weren't formally studied.
